Clinical Trial Detail

NCT ID NCT03574220
Title Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.